Sixth Wave Innovations Inc. Granted MIPS Patent for Extraction and Purification of Lithium, Mercury, and Scandium

Biotech & MedTech, Technology

March 29, 2022 (Source) — Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or the “Company“), a world leader in molecular imprinting technology, announced today that the United States Patent and Trademark Office has granted the Company a patent for its unique method of metal extraction and purification using molecularly imprinted polymers. (“MIPS“).

This patent extends the Company’s existing patent portfolio to include methodologies relating to the molecularly imprinted polymers, which selectively bind to target metals ions, achieving more efficient metal extraction. The technique has been successfully commercialized by SIXW for precious metals. This patent focuses on highly valuable metals associated with the growing demand for green energy alternatives, advanced manufacturing, and environmental remediation.

With this patent issuance, Sixth Wave has advanced its intellectual property (“IP”) portfolio to over 9 issued patents, and 39 pending patents for molecular detection and extraction using MIPS and other molecular separation techniques.

Sixth Wave has positioned itself as a leader in technology innovation that allows cleaner and more environmentally friendly exploitation of natural resources. In particular, lithium demand is expected to double over the next six years1. Extraction and purification technology that does not require excessive consumption of water, long production times, and high energy consumption associated with hard-rock lithium mining. Moreover, the prolific growth of lithium batteries will necessitate innovative and efficient recycling methods to meet expected demand. Our MIPs have the potential to allow direct purification from these resources with greater efficiency and lower environmental impact than existing technology. I am proud of our team and their ability to create practical, and commercially viable new intellectual property using these techniques to solve challenging real-world problems,” said Dr. Gluckman, President and CEO of Sixth Wave.

Sixth Wave believes there are significant opportunities to monetize the Company’s metals purification MIPs being sold under the IXOS® brand name. This technology enables the delivery of efficient, scalable, environmentally friendly, and lower-cost solutions to our mining customers.

About Sixth Wave

Sixth Wave is a development stage nanotechnology company with patented technologies that focus on the extraction and detection of target substances at the molecular level using highly specialized molecularly imprinted polymers (MIPs). The Company is in the process of commercializing its Affinity™ cannabinoid purification system, as well as, IXOS®, a line of extraction polymers for the gold mining industry.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit:

Jon Gluckman
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: [email protected]

Cautionary Notes

This press release includes certain statements that may be deemed “forward-looking statements” including statements regarding the planned features of the MIPs technology. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the MIPs technology are subject to the risk that the MIPs technology may not prove to be successful in detecting virus targets effectively or at all, the uncertainty of medical product development, the uncertainty of timing or availability of required regulatory approvals, lack of track record of developing products for medical applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if its patent application is not successful. The Company has not yet completed the development of a prototype for the product that is subject of its patent application and has not yet applied for regulatory approval for the use of this product from any regulatory agency.

1 Source: